BPC-157 vs KLOW: Mechanism Comparison
Before diving into application-specific details, this table summarizes the core mechanistic differences between BPC-157 and KLOW that determine which peptide fits your research model. Primary Mechanism VEGF upregulation, angiogenesis, growth factor receptor ac
This comparison does not assign a generated winner or score.
- Before diving into application-specific details, this table summarizes the core mechanistic differences between BPC-157 and KLOW that determine which peptide fits your research model.
- Primary Mechanism
- VEGF upregulation, angiogenesis, growth factor receptor activation
- AMPK activation, autophagy induction, mitochondrial quality control
- Fundamentally different pathways. BPC-157 builds tissue, KLOW cleans cells
- Molecular Weight
- ~1419 Da (pentadecapeptide)
- ~650–700 Da (hexapeptide)
- KLOW's smaller size = faster distribution but also faster clearance
- Estimated Half-Life
- 4–6 hours (rodent models)
- 2–3 hours (rodent models)
- BPC-157 allows twice-daily dosing; KLOW often requires 3× daily or infusion
- Stability Profile
- Stable pH 1.0–14.0, survives gastric acid
- Acid-labile, requires parenteral administration
- BPC-157 uniquely viable for oral gavage protocols
- Key Research Applications
- Tendon/ligament repair, wound healing, GI ulceration, neuroprotection post-TBI
- Autophagy induction, protein aggregate clearance, metabolic regulation, longevity studies
- Choose based on endpoint: structural healing vs cellular maintenance
- Documented Efficacy
- 60–80% faster tendon healing in rodent injury models (J Orthop Res 2020)
- 35–45% increase in LC3-II autophagy marker in neuronal cultures
- Both show robust effects within mechanistically appropriate models
- Bottom Line
- First-choice peptide for tissue regeneration studies requiring neovascularization and collagen remodeling
- First-choice for cellular stress response, mitophagy, and protein homeostasis studies
- The difference between BPC-157 and KLOW is not potency. It's pathway